IL6 and chronic kidney disease: The Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition study22 was a randomized, controlled, double-blind, phase 2 clinical trial in patients with moderate-to-severe CKD and hsCRP ≥2 mg/L to observe the efficacy and safety of ziltivekimab, a fully human mAb against IL-6 ligand.